PPL Therapeutics is a biopharmaceutical company which is one of the world¡¯s leaders in the application of transgenic animal technologies to the development and production of human proteins for therapeutic and nutritional applications. PPL has a broad pipeline of diverse protein products including AAT, the Company¡¯s lead product, which is currently in Phase II clinical trials for cystic fibrosis. AAT is also under development for the treatment of congenital deficiency. PPL¡¯s other lead products are fibrinogen and bile salt stimulated lipase (BSSL). Transgenic production of human proteins involves the introduction of copies of human DNA into the genetic material of another species. The resulting transgenic animals express the human gene product (protein) in the mammary gland allowing its collection and purification during lactation. The technique offers the opportunity to produce human proteins economically and in potentially unlimited quantities. PPL has a world wide exclusive licence from the Roslin Institute to use the Institute¡¯s intellectual property relating to nuclear transfer (cloning) in the field of production of proteins for pharmaceutical and nutraceutical use in the milk of ruminant livestock and rabbits.
